GENR

[REALDEALS21]

Take a look at it ! HUGE volume today !

Tech analysis PLEASE by the pros !

[422fwhp]

"Macugen (EYET) has done well because it is a first mover. Other competitors are breathing down its neck. They include Lucentis from Genentech (DNA) and Evizon from Genaera (GENR), both of which are in phase 3 development. Both of these drugs have looked good so far, and I expect both to be approved. This will put substantial pressure on Macugen, and it could really put a hurt on sales. I doubt that Macugen grows much beyond 2006."

From:
http://www.fool.com/news/commentary/2005/commentary05082307.htm?source=eptyholnk303100&logvisit=y&npu=y

Much cheaper too...nice recent move.  Hopefully some TA experts can chime in...

[422fwhp]

SON FUEGO!!!

[shawFund]

Good pick. Actually I am about to pick it and found that it is already been picked.

EYET is a competitor of GENR nd was bought by OSIP.

So Genr will be a much better candidate and much cheaper.

Let us see how high it could fly.

[REALDEALS21]

Most likely it will close at or near the 200 MA line and tommorrow might see it bounce off that ! 

[422fwhp]

Good pick. Actually I am about to pick it and found that it is already been picked.

Ditto, I was watching it from another board. 

I jumped in at $2.50 ($old EYET ) but my gut was telling me to buy at $2.35....we shall see.

[setravis]

Falling Wedge (reversal)
To qualify as a reversal pattern,there must be a prior trend to reverse.
We have that,has been in a downtrending for some time.
If Evizon is approved,this could light the fire under GENR.
Which looks to be burning already.
Yesterday's candlestick took it above the 50-day ema,today's candlestick
closed above the 200-day ema. On 22 August,(Monday) it formed the candlestick pattern
Bullish Harami and from the movement of the stock up to today it looks to have confirmation of the pattern,with the last 3 days to the upside...nice
MACD...bullish,Stochastic on the way back up.

[422fwhp]

Tidbit of news...
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh29632_2005-08-26_19-32-02_n2666037_newsml

I added a little this morning expecting it to come down further.  Disregarding news, is the norm for a stock after a runnup to retract ~61.8% from the HIGH or the CLOSE?  I calculated from the high and came up with ~$2.25 (+/-)

...still learning...thx for the input.

laterz...Jody

[422fwhp]

Any TA technicians have input?  Would be much appreciated.   

Showing bullish except for last candle:
http://www.stockta.com/cgi-bin/analysis.pl?symb=GERN&num1=3&cobrand=&mode=stock

Holding above 50(MA) nicely.  IMO, it looks look it may come in (read: down) a little more but I'm not expert.

[422fwhp]

Up 7+% pm and looks to be breaking out again, imo.


Genaera Receives Patent for a Method for the Synthesis of Squalamine and Other Aminosterol Compounds

http://biz.yahoo.com/prnews/050908/nyth111.html?.v=23

PLYMOUTH MEETING, Pa., Sept. 8 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced issuance by the United States Patent and Trademark Office of patent number 6,933,383 entitled "Regioselective and Steroselective Oxidation of Fused Ring Systems Useful for the Preparation of Aminosterols." The patent covers a method for the synthesis of aminosterol compounds, such as EVIZON(TM) (squalamine lactate), squalamine for cancer and trodusquemine (MSI-1436). These compounds have been identified as anti-angiogenic agents, antibiotics and sodium hydrogen anti-porter (NHE) inhibitors. Patent expiry occurs in April 2021.


"The issuance of this patent further strengthens our robust intellectual property position surrounding EVIZON and squalamine for cancer," commented Roy C. Levitt, MD, Chief Executive Officer. "We are pleased to secure this patent as we believe EVIZON is the leading systemic, anti-angiogenic, investigative new drug in Phase III development for the treatment of wet age-related macular degeneration."

Genaera's discovery of aminosterols including squalamine and trodusquemine has been complimented by a combinatorial chemistry and biology program that produced many synthetic aminosterols. EVIZON is Genaera's lead product candidate currently in Phase III development for the treatment of "wet" age-related macular degeneration (AMD). Squalamine is in Phase II development in prostate cancer. Trodusquemine is a preclinical compound which may be useful as a treatment of obesity. Additional aminosterol compounds have demonstrated sufficient efficacy in preclinical models to encourage our pursuit of additional research that could lead to the development of a new treatment for inflammatory disorders.

About EVIZON(TM) and Squalamine

EVIZON (squalamine lactate) is a unique first-in-class synthetic small molecule administered systemically that directly interrupts and reverses multiple facets of the angiogenic process. Working within activated endothelial cells, squalamine inhibits growth factor signaling including VEGF, integrin expression, and reverses cytoskeletal formation, thereby resulting in endothelial cell inactivation and apoptosis. Systemically administered squalamine inhibits abnormal angiogenesis in rodent models of cancer, retinopathy of prematurity, and the development of choroidal neovascular membranes in rat models of AMD. Additional preclinical studies have demonstrated that systemic squalamine administration is effective in reaching abnormal ocular blood vessels in primates, and leads to partial regression and inhibition of new abnormal vessels in the eye. These results support the concept that squalamine may have a role in the treatment of human cancer and choroidal neovascular membrane formation that underlies the pathology of wet AMD.

About Trodusquemine

In preclinical studies, trodusquemine treatment regulated food intake and prevented weight gain in genetically obese, diet-induced obesity and normal rodents. Trodusquemine was capable of profoundly reducing fat stores, while maintaining normal water and electrolyte balance. Furthermore, trodusquemine prevented abnormal weight gain and re-established normal blood glucose levels in genetically obese mice with diabetes. Currently, preclinical studies of trodusquemine are supported by a $100,000 Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

About Genaera

Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has four products in development for the treatment of eye, cancer and respiratory disorders. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically "wet" age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.

[422fwhp]

Support at $2.22 (touched 3 times in the last two weeks).

Today's news (most saying the same thing...just wanted to post it all):

Genaera Announces $24.5 Million Direct Equity Placement
http://biz.yahoo.com/prnews/050912/nym164.html?.v=21

...from yahoo:
8:31AM Genaera announces $24.5 mln direct equity placement (GENR) 2.62 :Co receives purchase agreements from unaffiliated institutional investors for the purchase of 11.4 mln shares at $2.15 per share for aggregate proceeds of $24.5 mln pursuant to the co's shelf registration statement. In addition, warrants to purchase 3.42 mln shares were issued to the institutional investors with an exercise price of $3.15 per share.

http://biz.yahoo.com/cbsmb/050912/38dd4f7b70b3451bb12f2f7bd380c4d6.html?.v=1
NEW YORK (MarketWatch) -- Genaera Corp. said it's received stock purchase agreements from unaffiliated institutional investors for the sale of 11.4 million shares at $2.15 each. The company expects to receive proceeds of $24.5 million from the investment. Genaera also sold warrants to purchase 3.42 million common shares to institutional investors. The warrants have an exercise price of $3.15 a share.

Genaera gets new investors
http://biz.yahoo.com/bizj/050912/1162828.html?.v=1

[422fwhp]

Entry into Material Agreement, Other Events, Financial Statements and Exhibits
http://biz.yahoo.com/e/050913/genr8-k.html

Item 1.01. Entry into a Material Definitive Agreement

On September 9, 2005, Genaera Corporation (the "Company") received signed securities purchase agreements from unaffiliated institutional investors for the purchase of an aggregate of approximately 11.4 million shares (the "Shares") at $2.15 per share of registered common stock for aggregate proceeds of $24.5 million. The shares were offered through a prospectus supplement pursuant to the Company's effective shelf registration statement. In addition, warrants to purchase 3,420,000 shares of common stock were issued to the institutional investors. The warrants have an exercise price of $3.15 per share. A copy of the Securities Purchase Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In connection with the sale of the Shares, the Company is filing the Placement Agency Agreement relating thereto as part of this Current Report on Form 8-K as Exhibit 99.2."

---------------------------------------------------------------------------

Touched support again today. Is this considered consolidation?  Still holding.

[422fwhp]

The latest candle formation is almost like a bullish doji but without the gap down.  Would like to see a BWC tomorrow but then again who wouldn't 

Anyone playing this besides me?

http://www.stockta.com/cgi-bin/analysis.pl?symb=GENR&num1=3&cobrand=&mode=stock

[setravis]

May be ready to go some where.......
Falling Wedge (Reversal) Pattern.

Technicals
Percentage Gainer

Last Price Quote is:
13.63%above 13-day EMA
3.33%above 50-day EMA
RS Rating: 10 

Fundamentals
Key Data:
Market Cap (M): $96.15 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/09/2006
Last Analyst Rating: Buy

[setravis]

Potential..... had a little pull back.
Buy this below $1.50 and target sell point at $2.25 to 2.75

Support @ $1.42...1.29
Resistance @ 1.62...1.70...1.79

Technicals
MACD is Bullish

Last Price Quote is:
4.76%above 13-day EMA
-0.86%below 50-day EMA
RS Rating: 11 

Fundamentals
Key Data:
Market Cap (M): $103.02 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/09/2006
Last Analyst Rating: Buy